Like Passive Income? Then You'll Love These 3 Super Safe Dividend Stocks That Are Up Between 28% and 42% in 6 Months.

Source The Motley Fool

Investors often gravitate toward super safe dividend stocks to collect passive income and limit market volatility. But sometimes, even stodgy, boring companies can crush the market.

In the past six months (from May 29 to Nov. 29) Walmart (NYSE: WMT) is up a staggering 42.5%, Clorox (NYSE: CLX) is up 30.4%, and Kenvue (NYSE: KVUE) is up 27.6%. Here's what's driving all three stocks higher and why they have what it takes to continue raising their dividends for years to come.

A person smiles while mopping up a wooden floor.

Image source: Getty Images.

The anatomy of a breakout

With discount retailers like Dollar General and Dollar Tree hovering around 52-week lows and Target falling over 22% in a single day after its last earnings report, you may think that Walmart stock would be lying in the bargain bin. But Walmart is up a mind numbing 72% year to date.

When an established retailer like Walmart gains a big amount in a short period of time, it's usually because the company is doing something completely unexpected. Walmart has threaded the seemingly impossible needle of conveying everyday value for consumers while also attracting higher-income consumers.

In its recent quarter, Walmart said that its U.S. business delivered 5.3% comparable sales growth with notable market share gains in grocery and general merchandise. For the quarter, around 75% of market share gains in Walmart U.S. came from households earning more than $100,000.

So by delivering everyday value, Walmart has attracted consumers toward its discretionary goods during a period when so many retailers are struggling. It's not just pricing where Walmart is shining. Walmart's services, such as Walmart+ contactless delivery service, Walmart Marketplace (business-to-business e-commerce tools), and Walmart Connect (tools for sellers) are all thriving.

To top it all off, Walmart is using artificial intelligence and machine learning to gain customer insights and improve the in-store experience, digital offerings, and its internal processes.

Walmart is in a league of its own, but the stock has become significantly more expensive, and the yield has fallen to just 1%. However, Walmart is a Dividend King with 51 consecutive years of dividend raises. In February, Walmart raised its dividend by 9%, and I would expect a double-digit-percentage raise this coming February.

Add it all up, and Walmart could still be worth a closer look for investors who don't mind a lower yield.

Expectations were too low for Clorox

With 40 consecutive years of dividend raises and a 2.9% yield, Clorox immediately stands out as a passive income powerhouse. But unlike Walmart, Clorox isn't at the top of its game -- far from it right now.

On Oct. 30, Clorox reported first-quarter fiscal 2025 results. It raised its full-year fiscal 2025 earnings guidance but reaffirmed organic sales growth of just 3% to 5%. Clorox continues to spend a ton on advertising, which ate into earnings for the recent quarter.

Given the challenges, investors may wonder why the stock hit an all-time high. The simple answer is that Wall Street cares more about where a company is going than where it has been. And there are plenty of reasons to believe Clorox is headed in the right direction.

The last few years have been a mess for Clorox. There was the pandemic, which initially was a boon for Clorox as customers flocked to cleaning products. But Clorox overestimated demand trends, believing there would be a sustained shift in buyer behavior toward more hygiene and cleaning. That left Clorox overextended when pandemic restrictions eased.

And to make matters worse, Clorox was hit by a cyberattack in 2023. Its first-quarter fiscal 2024 sales fell 20%, and diluted earnings per share slumped 75%. So given all these challenges, fiscal 2025 is truly the first "normal year" we've seen from Clorox for some time.

It's also worth mentioning that Clorox's stock price is up just 12.8% over the last five years. So the recent surge may partially be the market catching up to the fact that Clorox is returning to growth.

Clorox still has a way to go before returning to its high-margin form. However, the stock could still be worth buying for patient investors looking for higher-yield options in the consumer staples sector.

Kenvue is a rare value in an expensive market

In August 2023, Johnson & Johnson spun off its low-growth consumer health division so it could focus on its pharmaceutical and medical device business segments. The resulting company, Kenvue, was named after "ken" -- meaning knowledge -- and "vue" -- meaning sight -- to showcase the company's insight into personal health solutions.

The spinoff provided greater insight into the performance of legacy brands like Aveeno, Band-Aid, Listerine, Neutrogena, and Tylenol. As is the case with most spinoffs, the market needed time to adjust to Kenvue. Even after its recent run-up, Kenvue is down 10.5% since its inception after undergoing an initial sell-off in late 2023, followed by an additional tumble over this past summer.

Kenvue is far from a high-octane growth machine. But it is an ultra-stable company that should be able to grow its dividend over time steadily. Kenvue is technically a Dividend King because it inherited J&J's status. But Kenvue's recent dividend raise was just 2.5%. Kenvue needs to deliver larger raises to be considered a passive income powerhouse. But the good news is that Kenvue already has a sizable yield of 3.4% and a reasonable forward P/E ratio of 21.1.

Risk-averse investors focused more on capital preservation than capital appreciation may want to look closer at this high-yield value stock.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

  • Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $363,671!*
  • Apple: if you invested $1,000 when we doubled down in 2008, you’d have $45,954!*
  • Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $486,533!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

See 3 “Double Down” stocks »

*Stock Advisor returns as of December 2, 2024

Daniel Foelber has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Kenvue, Target, and Walmart. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2026 $13 calls on Kenvue. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Japanese Yen weakens amid fading safe-haven demand after Trump delays tariffsThe Japanese Yen (JPY) drifts lower during the Asian session on Tuesday as US President Donald Trump's decision to delay plans to impose trade tariffs on Canada and Mexico dents demand for traditional safe-haven assets.
Author  FXStreet
Yesterday 02: 38
The Japanese Yen (JPY) drifts lower during the Asian session on Tuesday as US President Donald Trump's decision to delay plans to impose trade tariffs on Canada and Mexico dents demand for traditional safe-haven assets.
placeholder
Novo Nordisk Q4 2024 Results: Will Wegovy Continue to Shine?TradingKey - One of the biggest trends in the healthcare space over the past few years has been the rise of so-called GLP-1 drugs.These can help treat type 2 diabetes and obesity but one of the other
Author  TradingKey
Yesterday 02: 41
TradingKey - One of the biggest trends in the healthcare space over the past few years has been the rise of so-called GLP-1 drugs.These can help treat type 2 diabetes and obesity but one of the other
placeholder
Could We See Dogecoin And Shiba Inu Prices Continue to Rise As We Take A Look Into New Sensation RemittixThere were brief moments last week where it seemed possible that both Shiba Inu and Dogecoin might see sustained rises. This theory has been put to bed in the last 24 hours as things have taken a dramatic turn for the worse. Both assets have plummeted in value and continue to exhibit downward pressure. This […]
Author  Cryptopolitan
5 hours ago
There were brief moments last week where it seemed possible that both Shiba Inu and Dogecoin might see sustained rises. This theory has been put to bed in the last 24 hours as things have taken a dramatic turn for the worse. Both assets have plummeted in value and continue to exhibit downward pressure. This […]
placeholder
Gold price continues scaling higher; fresh record high and countingGold price (XAU/USD) prolongs its upward trajectory through the Asian session on Wednesday and advances to a fresh all-time peak, around the $2,854 region in the last hour.
Author  FXStreet
5 hours ago
Gold price (XAU/USD) prolongs its upward trajectory through the Asian session on Wednesday and advances to a fresh all-time peak, around the $2,854 region in the last hour.
placeholder
AMD Reports Record Q4 Revenue, Shares Plunge 9% on Data Center MissAMD, a global semiconductor giant, saw its stock price fluctuate dramatically after releasing its Q4 2024 earnings report, despite surpassing consensus estimates on both the top and bottom lines. The
Author  TradingKey
2 hours ago
AMD, a global semiconductor giant, saw its stock price fluctuate dramatically after releasing its Q4 2024 earnings report, despite surpassing consensus estimates on both the top and bottom lines. The
goTop
quote